Severe mendelian susceptibility to mycobacterial diseases due to complete IFNG deficiency

Advocacy intelligence hub — real-time data for patient organizations

View full disease page →Search clinical trials →
Download CSV

At a Glance

Live from database

Regulatory Watchboard

1 event
Dec 2012

VARIZIG: FDA approved

Post exposure prophylaxis of varicella in high risk individuals to reduce the severity of varicella

FDAcompleted

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

1 program

FINANCIAL LANDSCAPE SUMMARY

1

Total programs

1

Open now

1

Copay cards

Copay Assistance1

VARIZIG

Cangene bioPharma, Inc.

OpenContact for details

View all support programs on disease page →

Clinical Trial Landscape

No active clinical trials currently recruiting for Severe mendelian susceptibility to mycobacterial diseases due to complete IFNG deficiency.
Search all trials →
Search clinical trials for Severe mendelian susceptibility to mycobacterial diseases due to complete IFNG deficiency

Recent News & Research

No recent news articles indexed yet for Severe mendelian susceptibility to mycobacterial diseases due to complete IFNG deficiency.
Search PubMed for Severe mendelian susceptibility to mycobacterial diseases due to complete IFNG deficiency

Browse all Severe mendelian susceptibility to mycobacterial diseases due to complete IFNG deficiency news →

Specialist Network

No specialists currently listed for Severe mendelian susceptibility to mycobacterial diseases due to complete IFNG deficiency.

View all Severe mendelian susceptibility to mycobacterial diseases due to complete IFNG deficiency specialists →

Quick Actions